
SafeBeat Rx is a company focused on revolutionizing cardiac care through AI-powered technology, enabling remote patient monitoring (RPM) and therapeutic monitoring for various cardiac conditions. Their platform leverages proprietary machine learning algorithms to process data from third-party FDA-cleared devices like mobile ECGs and implantable cardiac monitors, providing clinicians with streamlined insights and treatment recommendations. Designed by clinicians for clinicians, the software prioritizes patient and clinician experience, aiming to expand access to digital health and remote care. The company's technology goes beyond diagnostics to potentially guide therapeutic interventions, with a stated goal of reducing healthcare costs and improving cardiovascular outcomes. While the product is under development and currently limited to investigational use, SafeBeat Rx has attracted significant attention and support from prominent figures in cardiology and the venture capital community.

SafeBeat Rx is a company focused on revolutionizing cardiac care through AI-powered technology, enabling remote patient monitoring (RPM) and therapeutic monitoring for various cardiac conditions. Their platform leverages proprietary machine learning algorithms to process data from third-party FDA-cleared devices like mobile ECGs and implantable cardiac monitors, providing clinicians with streamlined insights and treatment recommendations. Designed by clinicians for clinicians, the software prioritizes patient and clinician experience, aiming to expand access to digital health and remote care. The company's technology goes beyond diagnostics to potentially guide therapeutic interventions, with a stated goal of reducing healthcare costs and improving cardiovascular outcomes. While the product is under development and currently limited to investigational use, SafeBeat Rx has attracted significant attention and support from prominent figures in cardiology and the venture capital community.
Sector: Digital health — AI-driven cardiac/ECG software
Product status: Investigational / under development
Founders: Rachita Navara, MD; Kunj G. Patel, MD, MSc
Notable funding: Direct-to-Phase II NIH/NHLBI SBIR (~$2M) grant
Headcount (reported): 32 employees
Remote patient monitoring and therapeutic management for cardiac conditions, with emphasis on atrial fibrillation.
2021
Healthcare / Digital Health / Medical Software
Approximately $2,000,000
Award R44HL167294 to support clinical validation with UCSF; company also lists participation in accelerator/investor programs and other investors on record.
Crunchbase lists a grant on Nov 29, 2023 with LG Nova as a recent investor; specific amount redacted in records.
“Y Combinator; LG Nova; MedTech Innovator; Liquid 2 Ventures; Fusion Fund (named investors and program participants)”